Bolzon Bradley J PhD's Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Jul 21, 2021
- Accession no.
- 0000899243-21-029271
- Filed
- Jul 21, 2021
- Trade date
- Jul 19, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $1.26M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bolzon Bradley J PhDCIK 0001354345 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 19, 2021 | Common Shares | SSaleDisposed | −3,504 | $125.67F3 | −$440,347.68 | 155,327 | Indirect | |
| Jul 19, 2021 | Common Shares | SSaleDisposed | −4,472 | $126.41F5 | −$565,305.52 | 150,855 | Indirect | |
| Jul 19, 2021 | Common Shares | SSaleDisposed | −1,324 | $127.36F6 | −$168,624.64 | 149,531 | Indirect | |
| Jul 19, 2021 | Common Shares | SSaleDisposed | −700 | $128.71F7 | −$90,097 | 148,831 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $125.00 to $125.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $126.00 to $126.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $127.02 to $127.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.18 to $129.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
Referenced by the price of 1 transaction in Table I.